Anti-alpha-Gal antibody (Endogenous) (anti-Gal)

Anti-alpha-Gal antibodies are natural endogenous antibodies (primarily of the IgM, IgG, and IgA classes; in some allergic states, IgE) produced in humans, apes, and Old World monkeys in response to exposure to the carbohydrate α-galactosyl epitope (Galα1-3Galβ1-4GlcNAc-R)[1][3][5][8]. Humans do not produce the α-gal epitope due to inactivation of α-1,3-galactosyltransferase but generate large amounts of anti-α-Gal antibodies upon exposure to this epitope, which is widespread among bacteria, non-primate mammals, and some parasites[3][5][8]. These antibodies constitute up to 1% of circulating immunoglobulins in humans[1][5]. Anti-α-Gal IgM/IgG play important roles in immunity, including acting as an evolutionary barrier to infections by organisms expressing α-Gal, and mediating hyperacute rejection of xenografts[5][3][8]. Anti-α-Gal IgE, an aberrant isotype, is responsible for alpha-gal syndrome—a form of delayed, sometimes life-threatening, allergy following exposure to mammalian meat[4][5][7]. Anti-α-Gal antibodies are also being studied and exploited for vaccine targeting, tumor immunotherapy, and tissue regeneration (wound healing), but are themselves not a direct drug or therapeutic target in the classical sense—they are immune effectors, not a molecule or receptor to which therapeutics are designed to bind directly[1][5][6]. Therefore, the target name as provided ("Endogenous anti-alpha-Gal antibodies") does not refer to a canonical molecular target but rather to endogenous immune effector molecules. Notes: - This entry is marked as incorrect as a therapeutic drug target because endogenous antibodies are not receptors, enzymes, etc., but rather effector molecules of the immune system. The actual "target" in the classical sense would be the alpha-gal epitope (carbohydrate antigen), not anti-alpha-Gal antibodies themselves. - Anti-α-Gal antibody levels (especially IgE) serve as important biomarkers for patient selection and diagnosis in context of alpha-gal syndrome. - No drugs specifically "target" endogenous anti-Gal antibodies, though their levels and interactions are modified indirectly (e.g., in allergy, immunotherapy, and xenotransplantation contexts).

Other names

anti-Galanti-α-Gal antibodyanti-α-galactosyl antibodyendogenous anti-Gal antibodynatural anti-Gal antibody